Oxytocin and arginine-vasopressin have been identified chemically in the hypophysis of man (Light & du Vigneaud 1958) , ox (Turner, Pierce & du Vigneaud 1951; Pierce & du Vigneaud 1950) and horse (Acher, Chavet & Lenci 1958 ) while lysine-vasopressin rather than arginine-vasopressin is present in hog pituitary tissue (Lawler & du Vigneaud 1953) . In the hypophysis of fowls and lower vertebrates instead of vasopressin there is present another octapeptide, namely vasotocin or arginyl-8-oxytocin (Munsick 1959; Heller 1959; Pickering & Heller 1959; Sawyer et al. 1959) . In this substance arginine has replaced leucine in the oxytocin side chain. This structural change is responsible for the fact that the antidiuretic potency of vasotocin in chickens is higher than that of arginine-vasopressin; this latter substance being the most powerful inhibitor of diuresis known in mammals (Munsick, Sawyer & van Dyke 1958) .
It is possible that other polypeptides, of as yet undetermined structure, are present in the pituitary glands of mammals and lower vertebrates. One of these may be responsible for corticotrophin release (Ramachandran & Winnick 1957) . The pharmacology of polypeptides obtained from blood and bearing a similar action to those found in pituitary tissue will be discussed later.
INTERMEDIATE PRODUCTS BETWEEN OXYTOCIN AND VASOPRESSIN
Intermediates between oxytocin and vasopressin have been synthetized. One such compound is phenylalanyl-3-oxytocin (oxypressin) (Katsoyannis 1957) , which has activities similar to both oxytocin and vasopressin and the antidiuretic (Berde 1959) as are the strong basic aminoacids in the vasopressin side chain to its pressor effects (van Dyke 1959 (Berde & Cerletti 1959) .
Almost certainly the similarity in chemical structure of the various com¬ pounds explains their "overlapping" in terms of pharmacological actions. Thus in the frog, oxytocin has a greater antidiuretic effect than vasopressin and the contrary occurs in toads (van Dyke 1959) . In several species vasopressin has a more pronounced action than oxytocin on uterine muscle except during pregnancy and at the time of parturition.
DOES OXYTOCIN HAVE ANY PHYSIOLOGICAL EFFECTS APART FROM ITS UTERINE-STIMULATING ACTION?
The emphasis which has been placed on the uterine-stimulating activity of oxytocin explains why the observations of Fraser (1937, 1942) and Kuschinsky & Bundschuh ( 1939) on the effects of oxytocin on renal excretion have received so little attention. Nevertheless, the effect of oxytocin on urinary secretion is of great physiological importance. Neurohypophyseal extracts in which vasopressin has previously been inactivated by treatment with trypsin, cause marked diuretic effects in the rat (Croxatto & Croxatto unpubl.) . Also it is clear that pure oxytocin when given subcutaneously in the rat in a dose producing little or no effect on the uterus in vivo can still cause a marked increase of sodium excretion in the urine (Rosas et al., unpubl.; Croxatto & Croxatto, unpubl.) .
Adrenalectomy prevents the increase in water excretion which follows oxy¬ tocin administration in the rat (Croxatto et al. 1956 Peters 1959) . The effects of oxytocin on the excretion of water, sodium, potassium and chloride in thirsty animals increase after cortisone administration (Peters 1959) . In normal and hypophysectomised rats the joint administration of NaCl and deoxycorticosterone increase the effects of oxytocin on the kidney, an observa¬ tion not found if the animals are subjected to a diet poor in NaCl (Croxatto & Z,amorano 1957) . In the dog a dose of oxytocin 20 or 30 times higher than the minimum antidiuretic dose of vasopressin, produces a considerable in¬ crease in excretion ofsodium chloride and occasionally of potassium, when the urine flow is low (Brooks & Pickford 1957) . When administered during water diuresis the immediate effect of oxytocin is a moderatcantidiuresis (Brooks & Pickford 1958 ) although a larger dose (10 mU/g) under such conditions causes an increase in the excretion of electrolytes (Cross 1959; Pickford 1959) . It is possi¬ ble that some of the delayed effects of oxytocin are due to the central action because they are not observed when diabetes insipidus, produced by section of the supraoptic-hypophyseal tract is present (Pickford 1959 Barnafi et al. (1960) who showed that in rats given a high water load, an injection of 2.5 and 5 mU of oxytocin not only neutralises the sodium-retaining effect of 0.5^g of aldosterone but also causes an increase in urinary sodium excretion. Sodium excretion is unchanged in rats which at the same time receive 2.5 mU of oxytocin and 1.0 µg of aldo¬ sterone (Barnafi et al. 1960 ).
Other analogues of oxytocin octapeptide influence the excretion of electro¬ lytes. Valyl-oxytocin is qualitatively and quantitatively similar to oxytocin when tested for oxytocic activity in vitro provided that the test is performed on a rat uterus submerged in normal Tyrode solution. The effects of the two compounds on water Na and excretion are similar.
Arginine-and lysine-vasopressins in physiological antidiuretic doses do not affect the excretion ofsodium and potassium (Thorn 1959) but under other experi¬ mental conditions lysine-vasopressin and phenylalanyl-2-lysyl-vasopressin caused a significant increase in Na excretion in the two hours following injection (Rosas & Barnafi, unpubl.) . Arginine-vasopressin is more active than leucine-vaso-pressin, and still more than lysine-vasopressin in its effects on diuresis and on urinary osmolarity in hydrated rats and dogs ( Thorn 1959).
Insufficient data are available at present to explain the mode of action of oxytocin on the kidney. It is probable that its site of action is similar to that of vasopressin, viz. the renal tubules. Since the sodium-excreting and diuretic effects of oxytocin persist after inhibition of renal carbonic anhydrase by acetozelamide, it can be assumed that this action is independent of this enzyme (Croxatto & Labarca 1958 (Croxatto & Croxatto, unpubl. ). An important difference between the oxytocic effects of various polypeptides (angiotensins, anephrotensin, bradykinin) on the one hand and neuro-hypophyseal hor¬ mones on the other, is that in vivo contractions produced by the former group of substances are seldom if ever followed by rhytmic activity. Contrariwise, oxytocin, valyl-oxytocin, lysyl-vasopressin and phenylanyl-2-lysyl-vasopressin, in our experience, cause rhythmic contractions which last for several minutes in the rat uterus even in the dioestrous phase ; this effect is noted when dosages in excess of those required to produce a "threshold" response are used. All substances except bradykinin show a correlation between the effects in vivo and in vitro provided the in vitro studies were conducted using normal Tyrode solution.
Effects on renal excretion.
The injection of various polypeptides modifies the excretory function of the kidney under conditions generally used for the assay of antidiuretic hormone, e. g. pepsanurin is a polypeptide the antidiuretic action of which is well marked in rats given an excess water load, n^ngiotensins increase sodium excretion in dosages of 0.1 and 10/¿g/100 g body weight but such dosages are not responsible for the intense diuretic and sodium-excreting effects of renin in different tests (Barnafi et al., in press ). Anephrotensin has shown a marked antidiuretic effect in hydrated rats either unanaesthetised or under alcohol anaesthesia. Anephrotensin when injected along with renin decreases the effects of the latter in the kidney (Croxatto & Barnafi 1959; Molina 1959) .
The possibility that endogenous vasopressin in the sera of rats and dogs could modify the action of anephrotensin was excluded by drawing blood immediately after putting a tourniquet round the neck, thus excluding the circulation to the brain and preventing vasopressin discharge. In addition, similar results were obtained with sera from animals with diabetes insipidus.
Finally, it should be mentioned that on frequent occasions, the extracts were treated with thioglycolic acid in order to inactivate any vasopressin present.
Those pharmacologically active polypeptides which may be formed in the body by the action of endogenous enzymes may interfere with the specificity of bioassays for neurohypophyseal hormones. This is particularly so in the case of anephrotensin and bradykinin which can be produced by various manipulations (Croxatto & Barnafi 1959 ). The oxytocic substance described by Hawker & Robertson (1958) , for example, could well be anephrotensin or a similar polypeptide. It is worth noting that none of the polypeptides mentioned above have any action on the myo-epithelial cells of the mammary gland.
